Dissolution profiles of mesalazine formulations in vitro

Area of Science:

• Pharmacokinetics and Drug Delivery

Background:

• Mesalazine (5-ASA) is a key treatment for inflammatory bowel disease (IBD).
• Controlled-release formulations are designed to optimize mesalazine delivery and efficacy.
• Understanding in vitro dissolution is critical for predicting in vivo performance.

Purpose of the Study:

• To characterize and compare the in vitro dissolution profiles of three distinct controlled-release mesalazine formulations.
• To evaluate the influence of varying pH conditions (1.0, 6.0, and 7.5) on drug release kinetics.
• To assess the suitability of each formulation for targeted drug delivery in different gastrointestinal segments.

Main Methods:

• Utilized a closed-column dissolution apparatus for in vitro release studies.
• Tested three controlled-release mesalazine formulations: Pentasa, Asacol, and Salofalk.
• Determined dissolution profiles across three physiologically relevant pH values: 1.0, 6.0, and 7.5.

Main Results:

• Pentasa exhibited a reproducible, gradual dissolution profile, commencing immediately and completing within 20 hours across all tested pH values.
• Asacol demonstrated pH-dependent release, with rapid dissolution (1-3 hours) at pH 7.5 and minimal release at pH 1.0 and 6.0.
• Salofalk showed delayed release, with dissolution initiating after 2-3 hours at pH 7.5 and 6.0 (completing in 5-10 hours), and a significant lag time (10 hours) before release at pH 1.0 (completing in 23 hours).

Conclusions:

• The distinct in vitro dissolution characteristics suggest differential suitability of Pentasa, Asacol, and Salofalk for specific therapeutic targets within the gastrointestinal tract.
• Asacol's profile aligns with ileal or colonic release, while Salofalk's delayed release may target the distal colon.
• Pentasa's consistent release offers broader applicability across different gastrointestinal pH environments.